Arcellx Acquired in Cash-and-CVR Deal, Going Private
TipRanks (Tue, 28-Apr 4:55 PM ET)
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Business Wire (Tue, 28-Apr 8:45 AM ET)
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 19-Mar 2:02 PM ET)
Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders
Globe Newswire (Thu, 19-Mar 8:00 AM ET)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--TALK, UNF, ACLX, and FONR
PRNewswire (Wed, 18-Mar 2:39 PM ET)
Globe Newswire (Tue, 17-Mar 12:56 PM ET)
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 16-Mar 11:00 AM ET)
Business Wire (Fri, 13-Mar 4:06 PM ET)
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 9-Mar 2:30 PM ET)
Globe Newswire (Thu, 5-Mar 1:36 PM ET)
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Arcellx trades on the NASDAQ stock market under the symbol ACLX.
As of May 1, 2026, ACLX stock price was flat at $115.07 with million shares trading.
ACLX has a beta of -0.24, meaning it tends to be less sensitive to market movements. ACLX has a correlation of 0.00 to the broad based SPY ETF.
ACLX has a market cap of $6.65 billion. This is considered a Mid Cap stock.
Last quarter Arcellx reported $2 million in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.05.
In the last 3 years, ACLX traded as high as $115.13 and as low as $30.74.
The top ETF exchange traded funds that ACLX belongs to (by Net Assets): VTI, VB, VBK, VXF, VTWO.
ACLX has outperformed the market in the last year with a return of +75.6%, while the SPY ETF gained +30.4%. In the last 3 month period, ACLX beat the market returning +68.5%, while SPY returned +4.4%. However, in the most recent 2 weeks ACLX has underperformed the stock market by returning 0.0%, while SPY returned +1.5%.
ACLX support price is $115.01 and resistance is $115.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACLX shares will trade within this expected range on the day.
